Click here to read the Point/Counter to this Cover Story.
The introduction of the first disease-modifying therapies fundamentally transformed the management of geographic atrophy and brought new changes and challenges in clinical practice, workflow and capacity.
The FDA approved complement inhibitors Syfovre (pegcetacoplan injection, Apellis) and Izervay (avacincaptad pegol intravitreal solution, Astellas) in 2023, and since then, the approach to managing intermediate age-related macular degeneration has shifted from solely using oral supplements and observation to the possibility of actively